{"groups":[{"description":"MEDI4736 (Durvalumab) + Tremelimumab","id":"FG000","title":"Combination Therapy"},{"description":"MEDI4736 (Durvalumab)","id":"FG001","title":"Monotherapy"},{"description":"Standard of Care Chemotherapy Treatment","id":"FG002","title":"Standard of Care"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"255"},{"groupId":"FG001","numSubjects":"262"},{"groupId":"FG002","numSubjects":"270"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"3"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"7"},{"groupId":"FG002","numSubjects":"12"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"84"},{"groupId":"FG001","numSubjects":"76"},{"groupId":"FG002","numSubjects":"59"}],"type":"participants ongoing at data cut-off"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"342"},{"groupId":"FG001","numSubjects":"346"},{"groupId":"FG002","numSubjects":"344"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"340"},{"groupId":"FG001","numSubjects":"345"},{"groupId":"FG002","numSubjects":"313"}],"type":"Received Treatment"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"342"},{"groupId":"FG001","numSubjects":"346"},{"groupId":"FG002","numSubjects":"344"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}